Pharmaceutical

AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC.

Jun 15, 2025 - 06:00
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC.
Read the original article

Tags:

Previous Article

BathMat Clinical Trial Initiated Across NHS Trusts to Alleviate Staff Burden and...

Next Article

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Bankrupt Pear’s addiction treatments acquired by virtual care company

STAT+: Bankrupt Pear’s addiction treatments acquired by...

Dec 13, 2023

Latozinemab by Alector for Frontotemporal Dementia (FTD): Likelihood of Approval

Latozinemab by Alector for Frontotemporal Dementia (FTD...

Dec 4, 2023

STAT+: Pharmacies fear New Year’s financial squeeze from Biden administration rule

STAT+: Pharmacies fear New Year’s financial squeeze fro...

Jan 2, 2024